Interestingly, the combination therapy of the three XYS preparations with LT4 did not significantly increase FT3 and FT4 levels, suggesting that exogenous thyroid hormone supplementation may not be conducive to the natural recovery of thyroid function in HT patients. The gene discussed is TG; the disease is hematocrit.